Clinical Trials
8 trialsNCT07601737 2026-05-22
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT02270814 2026-05-05
CACTUX
Washington University School of Medicine
Phase 2 Active not recruiting
NCT02495896 2026-04-29
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT07423078 2026-04-13
WOLF
University of Pittsburgh
Phase 2 Recruiting
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04831320 2025-12-30
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor
Washington University School of Medicine
Phase 2 Active not recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06009861 2025-06-06
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Peking University Hospital of Stomatology
Phase 2 Active not recruiting